{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,6]],"date-time":"2026-03-06T02:00:51Z","timestamp":1772762451203,"version":"3.50.1"},"reference-count":24,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2011,2,19]],"date-time":"2011-02-19T00:00:00Z","timestamp":1298073600000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/2.0"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["World J Urol"],"published-print":{"date-parts":[[2011,4]]},"DOI":"10.1007\/s00345-011-0655-6","type":"journal-article","created":{"date-parts":[[2011,2,18]],"date-time":"2011-02-18T09:27:38Z","timestamp":1298021258000},"page":"149-155","source":"Crossref","is-referenced-by-count":15,"title":["The muscarinic receptor antagonist propiverine exhibits \u03b11-adrenoceptor antagonism in human prostate and porcine trigonum"],"prefix":"10.1007","volume":"29","author":[{"given":"Melinda","family":"Wuest","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lambertus P.","family":"Witte","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Martina B.","family":"Michel-Reher","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Stefan","family":"Propping","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Manfred","family":"Braeter","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gerhard J.","family":"Strugala","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Manfred P.","family":"Wirth","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Martin C.","family":"Michel","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ursula","family":"Ravens","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2011,2,19]]},"reference":[{"key":"655_CR1","first-page":"525","volume":"12","author":"H Saito","year":"1999","unstructured":"Saito H, Yamada T, Oshima H et al (1999) A comparative study of the efficacy and safety of tamsulosin hydrochloride (Harnal capsules) alone and in combination with propiverine hydrochloride (BUP-4 tablets) in patients with prostatic hypertrophy associated with pollakiuria and\/or urinary incontinence. Jpn J Urol Surg 12:525\u2013536","journal-title":"Jpn J Urol Surg"},{"key":"655_CR2","doi-asserted-by":"publisher","first-page":"1334","DOI":"10.1097\/01.ju.0000173630.94559.fd","volume":"174","author":"K-S Lee","year":"2005","unstructured":"Lee K-S, Choo M-S, Kim D-Y et al (2005) Combination treatment with propiverine hydrochloride plus doxazosin controlled release gastrointestinal therapeutic system formulation for overactive bladder and coexisting benign prostatic obstruction: a prospective, randomized, controlled multicenter study. J Urol 174:1334\u20131338","journal-title":"J Urol"},{"key":"655_CR3","doi-asserted-by":"publisher","first-page":"1280","DOI":"10.1111\/j.1442-2042.2006.01538.x","volume":"13","author":"O Maruyama","year":"2006","unstructured":"Maruyama O, Kawachi Y, Hanazawa K et al (2006) Naftopidil monotherapy vs naftopidil and an anticholinergic agent combined therapy for storage symptoms associated with benign prostatic hyperplasia: a prospective randomized controlled study. Int J Urol 13:1280\u20131285","journal-title":"Int J Urol"},{"key":"655_CR4","doi-asserted-by":"publisher","first-page":"307","DOI":"10.1080\/00365590902836740","volume":"43","author":"T Yokoyama","year":"2009","unstructured":"Yokoyama T, Uematsu K, Watanabe T et al (2009) Naftopidil and propiverine hydrochloride for treatment of male lower urinary tract symptoms suggestive of benign prostatic hyperplasia and concomitant overactive bladder: a prospective randomized controlled study. Scand J Urol Nephrol 43:307\u2013314","journal-title":"Scand J Urol Nephrol"},{"key":"655_CR5","doi-asserted-by":"publisher","first-page":"87","DOI":"10.1007\/s00210-006-0103-0","volume":"374","author":"M Wuest","year":"2006","unstructured":"Wuest M, Weiss A, Waelbrock M et al (2006) Propiverine and metabolites: differences in binding to muscarinic receptors and in functional models of detrusor contraction. Naunyn-Schmiedeberg\u2019s Arch Pharmacol 374:87\u201397","journal-title":"Naunyn-Schmiedeberg\u2019s Arch Pharmacol"},{"key":"655_CR6","doi-asserted-by":"publisher","first-page":"365","DOI":"10.1016\/S0022-5347(05)00017-0","volume":"175","author":"S Maruyama","year":"2006","unstructured":"Maruyama S, Oki T, Otsuka A et al (2006) Human muscarinic receptor binding characteristics of antimuscarinic agents to treat overactive bladder. J Urol 175:365\u2013369","journal-title":"J Urol"},{"key":"655_CR7","doi-asserted-by":"publisher","first-page":"177","DOI":"10.1016\/0014-2999(96)00197-5","volume":"305","author":"S-C Chueh","year":"1996","unstructured":"Chueh S-C, Guh J-H, Chen J et al (1996) Inhibition by tamsulosin of tension responses of human hyperplastic prostate to electrical field stimulation. Eur J Pharmacol 305:177\u2013180","journal-title":"Eur J Pharmacol"},{"key":"655_CR8","doi-asserted-by":"publisher","first-page":"449","DOI":"10.1007\/s00210-007-0208-0","volume":"377","author":"EP Frazier","year":"2008","unstructured":"Frazier EP, Peters SLM, Braverman AS et al (2008) Signal transduction underlying control of urinary bladder smooth muscle tone by muscarinic receptors and \u03b2-adrenoceptors. Naunyn-Schmiedeberg\u2019s Arch Pharmacol 377:449\u2013462","journal-title":"Naunyn-Schmiedeberg\u2019s Arch Pharmacol"},{"key":"655_CR9","doi-asserted-by":"publisher","first-page":"431","DOI":"10.1007\/s00210-007-0231-1","volume":"376","author":"T Christ","year":"2008","unstructured":"Christ T, Wettwer E, Wuest M et al (2008) Electrophysiological profile of propiverine\u2014relationship to cardiac risk. Naunyn-Schmiedeberg\u2019s Arch Pharmacol 376:431\u2013440","journal-title":"Naunyn-Schmiedeberg\u2019s Arch Pharmacol"},{"key":"655_CR10","doi-asserted-by":"publisher","first-page":"608","DOI":"10.1038\/sj.bjp.0706244","volume":"145","author":"M Wuest","year":"2005","unstructured":"Wuest M, Hecht J, Christ T et al (2005) Pharmacodynamics of propiverine and three of its metabolites on detrusor contraction. Br J Pharmacol 145:608\u2013619","journal-title":"Br J Pharmacol"},{"key":"655_CR11","doi-asserted-by":"publisher","first-page":"659","DOI":"10.1007\/BF00167244","volume":"348","author":"H Tokuno","year":"1993","unstructured":"Tokuno H, Chowdhury JU, Tomita T (1993) Inhibitory effects of propiverine on rat and guinea-pig urinary bladder muscle. Naunyn-Schmiedeberg\u2019s Arch Pharmacol 348:659\u2013662","journal-title":"Naunyn-Schmiedeberg\u2019s Arch Pharmacol"},{"key":"655_CR12","doi-asserted-by":"publisher","first-page":"2454","DOI":"10.1016\/j.lfs.2007.04.002","volume":"80","author":"S Uchida","year":"2007","unstructured":"Uchida S, Kurosawa S, Fujino T et al (2007) Binding activities by propiverine and its N-oxide metabolites of L-type calcium channel antagonist receptors in the rat bladder and brain. Life Sci 80:2454\u20132460","journal-title":"Life Sci"},{"key":"655_CR13","doi-asserted-by":"publisher","first-page":"118","DOI":"10.1124\/jpet.107.130021","volume":"324","author":"H-L Zhu","year":"2008","unstructured":"Zhu H-L, Brain KL, Aishima M et al (2008) Actions of two main metabolites of propiverine (M-1 and M-2) on voltage-dependent L-type Ca2+ currents and Ca2+ transients in murine urinary bladder myocytes. J Pharmacol Exp Ther 324:118\u2013127","journal-title":"J Pharmacol Exp Ther"},{"key":"655_CR14","doi-asserted-by":"publisher","first-page":"491","DOI":"10.1007\/s00210-007-0242-y","volume":"377","author":"K-S Lee","year":"2008","unstructured":"Lee K-S, Lee HW, Han DH (2008) Does anticholinergic medication have a role in treating men with overactive bladder and benign prostatic hyperplasia? Naunyn-Schmiedeberg\u2019s Arch Pharmacol 377:491\u2013501","journal-title":"Naunyn-Schmiedeberg\u2019s Arch Pharmacol"},{"key":"655_CR15","doi-asserted-by":"publisher","first-page":"934","DOI":"10.1002\/nau.20500","volume":"26","author":"K-E Andersson","year":"2007","unstructured":"Andersson K-E (2007) LUTS treatment: future treatment options. Neurourol Urodyn 26:934\u2013947","journal-title":"Neurourol Urodyn"},{"key":"655_CR16","doi-asserted-by":"publisher","first-page":"2429","DOI":"10.1517\/14656566.6.14.2429","volume":"6","author":"A Athanasopoulos","year":"2005","unstructured":"Athanasopoulos A, Perimenis P (2005) Efficacy of the combination of an \u03b11-blocker with an anticholinergic agent in the treatment of lower urinary symptoms associated with bladder outlet obstruction. Exp Opin Pharmacother 6:2429\u20132433","journal-title":"Exp Opin Pharmacother"},{"key":"655_CR17","doi-asserted-by":"publisher","first-page":"S88","DOI":"10.1038\/sj.bjp.0706619","volume":"147","author":"MC Michel","year":"2006","unstructured":"Michel MC, Vrydag W (2006) \u03b11-, \u03b12- and \u03b2-adrenoceptors in the urinary bladder, urethra and prostate. Br J Pharmacol 147:S88\u2013S119","journal-title":"Br J Pharmacol"},{"key":"655_CR18","doi-asserted-by":"publisher","first-page":"145","DOI":"10.1016\/j.ejphar.2005.09.040","volume":"524","author":"M Wuest","year":"2005","unstructured":"Wuest M, Braeter M, Schoeberl C et al (2005) Juvenile pig detrusor: effects of propiverine and three of its metabolites. Eur J Pharmacol 524:145\u2013148","journal-title":"Eur J Pharmacol"},{"key":"655_CR19","doi-asserted-by":"publisher","first-page":"329","DOI":"10.1007\/s00210-010-0493-x","volume":"381","author":"S Propping","year":"2010","unstructured":"Propping S, Braeter M, Grimm M-O et al (2010) Anticholinergic effects of cis- and trans-isomers of two metabolites of propiverine. Naunyn-Schmiedeberg\u2019s Arch Pharmacol 381:329\u2013338","journal-title":"Naunyn-Schmiedeberg\u2019s Arch Pharmacol"},{"key":"655_CR20","doi-asserted-by":"publisher","first-page":"S80","DOI":"10.1038\/sj.bjp.0706560","volume":"147","author":"SS Hegde","year":"2006","unstructured":"Hegde SS (2006) Muscarinic receptors in the bladder: from basic research to therapeutics. Br J Pharmacol 147:S80\u2013S87","journal-title":"Br J Pharmacol"},{"key":"655_CR21","doi-asserted-by":"publisher","first-page":"1243","DOI":"10.2165\/00003088-200342140-00004","volume":"42","author":"DRP Guay","year":"2003","unstructured":"Guay DRP (2003) Clinical pharmacokinetics of drugs used to treat urge incontinence. Clin Pharmacokin 42:1243\u20131285","journal-title":"Clin Pharmacokin"},{"key":"655_CR22","doi-asserted-by":"publisher","unstructured":"Oelke M, Murgas S, Baumann I et al (2011) Efficacy of propiverine ER with or without \u03b1-blockers related to maximum urinary flow rate in adult men with OAB: results of a 12-week, multicenter, non-interventional study. World J Urol. doi:\n                    10.1007\/s00345-011-0654-7","DOI":"10.1007\/s00345-011-0654-7"},{"key":"655_CR23","doi-asserted-by":"publisher","first-page":"570","DOI":"10.1177\/0091270008315314","volume":"48","author":"K May","year":"2008","unstructured":"May K, Westphal K, Giessmann T et al (2008) Disposition and antimuscarinic effects of the urinary bladder spasmolytics propiverine: influence of dosage forms and circadian-time rhtyhms. J Clin Pharmacol 48:570\u2013579","journal-title":"J Clin Pharmacol"},{"key":"655_CR24","doi-asserted-by":"publisher","first-page":"1314","DOI":"10.1124\/dmd.110.033233","volume":"38","author":"S Yamada","year":"2010","unstructured":"Yamada S, Ito Y, Taki Y et al (2010) The N-oxide metabolite contributes to bladder selectivity resulting from oral propiverine: muscarinic receptor binding and pharmacokinetics. Drug Metab Dispos 38:1314\u20131321","journal-title":"Drug Metab Dispos"}],"container-title":["World Journal of Urology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00345-011-0655-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s00345-011-0655-6\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00345-011-0655-6.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00345-011-0655-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,4,7]],"date-time":"2019-04-07T08:18:56Z","timestamp":1554625136000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s00345-011-0655-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2011,2,19]]},"references-count":24,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2011,4]]}},"alternative-id":["655"],"URL":"https:\/\/doi.org\/10.1007\/s00345-011-0655-6","relation":{},"ISSN":["0724-4983","1433-8726"],"issn-type":[{"value":"0724-4983","type":"print"},{"value":"1433-8726","type":"electronic"}],"subject":[],"published":{"date-parts":[[2011,2,19]]}}}